MedTrace Logo

In It To Quit: Commitment Contracts for Smoking Cessation

NCT02596061 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 311

Last updated 2018-01-26

No results posted yet for this study

Summary

This study aims to examine whether a combination of positive and negative commitment devices is effective at inducing long-term smoking cessation in smokers from a low-to-moderate income background. Investigators will randomly assign patients of a multi-site clinic in Connecticut to receive one or both of a succession of two commitment contracts. First, a two-month reward contract will pay participants for (a) engaging in clinic and web-based activities that support smoking cessation and (b) quitting smoking, as measured at period end. Second, a four-month deposit contract will invite participants to commit funds which they forfeit unless they abstain from smoking over the entire period. A random subset of participants will also have the option to pre-commit to the deposit contract at study enrollment. Reward payout and deposit recovery will be conditional on biochemical verification of self-reported abstinence. Investigators will conduct follow-up biochemical verification at 12 months to observe whether abstinence persists after removal of incentives. The primary outcome of interest will be continuous abstinence from smoking between months 2 and 12, i.e. biochemically verified abstinence at all three measurements. A short baseline and endline survey will also be administered to measure characteristics and outcomes related to smoking behavior.

Conditions

  • Smoking

Interventions

BEHAVIORAL

Deposit Contract

Contracts prompt patients to put money they have earned at stake on a commitment to remain smoke-free for a longer period of time.

OTHER

Incentives

Patients receive incentives for completing smoking cessation activities.

Sponsors & Collaborators

  • Innovations for Poverty Action

    collaborator OTHER

  • Yale University

    collaborator OTHER

  • Community Health Center, Inc.

    lead INDUSTRY

Principal Investigators

  • Daren Anderson, MD · Vice President/Director of Weitzman Institute/Chief Quality Officer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2017-11-30
Completion
2017-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02596061 on ClinicalTrials.gov